Clik here to view.
GI Innovation Announces New Clinical Trial Collaboration and Supply Agreement...
SEOUL, South Korea The South Korean biotech company GI Innovation announced today that it has signed a clinical trial collaboration and supply agreement with MSD (a tradename of Merck& Co.,...
View ArticleClik here to view.
Zai Lab to Present Preliminary Data From Phase 1 Trial of ZL-1218, an...
SHANGHAI & CAMBRIDGE, Mass. Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that data from a Phase 1 study of ZL-1218, the company’s anti-CCR8 antibody, will be presented in a poster...
View ArticleClik here to view.
BeiGene to Present at the Morgan Stanley 22nd Annual Global Healthcare...
SAN MATEO, Calif. BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will participate in the Morgan Stanley 22nd Annual Global Healthcare...
View ArticleClik here to view.
Clik here to view.
ヒストソニックス、李嘉誠財団と提携し、香港で初のヒストトリプシープログラムを立ち上げ
ミネアポリス （ビジネスワイヤ） — Edison™ヒストトリプシーシステムの開発および製造を行う 本プレスリリースではマルチメディアを使用しています。リリースの全文はこちらをご覧ください。：https://www.businesswire.com/news/home/20240828053000/ja/ Mr. Li Ka-shing Gifts Histotripsy Systems to...
View ArticleClik here to view.
HighField Biopharmaceuticals Files IND in China for Clinical Trial of HF50, a...
HANGZHOU, China HighField Biopharmaceuticals, a clinical stage company using lipid-based therapeutics to treat cancer, diabetes and other diseases, announced today it has filed an investigational...
View ArticleClik here to view.
Clik here to view.
PHC Launches LiCellMoTM Live Cell Metabolic Analyzer for Real-Time...
TOKYO PHC Corporation Biomedical Division (headquarters: Chiyoda-ku, Tokyo, President: Nobuaki Nakamura; hereafter Biomedical Division) announced today the commercial launch of LiCellMo, a live cell...
View ArticleClik here to view.
PHC、細胞の代謝変化をリアルタイムに可視化するライブセル代謝分析装置「LiCellMoTM（リセルモ）」を発売
東京 （ビジネスワイヤ） — PHC株式会社 バイオメディカ事業部（本社：東京都千代田区、代表取締役社長：中村...
View ArticleClik here to view.
ヒストソニックス®、#HOPE4LIVERピボタル試験の結果を発表
ミネアポリス （ビジネスワイヤ） — Edison®ヒストトリプシーシステムの開発および製造を行うヒストソニックス(www.histosonics.com)...
View ArticleClik here to view.
Daiichi Sankyo Unveils New Research Across Industry-Leading ADC Portfolio in...
BASKING RIDGE, N.J. Daiichi Sankyo (TSE: 4568) will present new clinical research across its antibody drug conjugate (ADC) portfolio with more than 25 abstracts across multiple types of cancer at...
View ArticleClik here to view.
Shionogi Continues Global Commitment to Advances in Infectious Disease with...
FLORHAM PARK, N.J. Shionogi Inc., the United States subsidiary of Shionogi & Co., Ltd., (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.) will have 22 scientific...
View ArticleClik here to view.
PharmaEssentia Announces Licensing Agreement with FORUS Therapeutics to...
BURLINGTON, Mass. PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in...
View ArticleClik here to view.
PHC推出LiCellMoTM活细胞代谢分析仪，用于细胞和基因治疗中细胞代谢的实时可视化
东京 (美国商业资讯)– PHC Corporation生物医学事业部（总部：东京都千代田区，总裁：Nobuaki...
View ArticleClik here to view.
Novotech Releases 2024 Report on Pancreatic Cancer Clinical Trials and Drug...
BOSTON Novotech, the global full-service clinical Contract Research Organization (CRO) that partners with biotech companies to accelerate the development of advanced and novel therapeutics at every...
View ArticleClik here to view.
诺为泰发布2024年胰腺癌全球临床试验和药物开发报告
美国波士顿 (美国商业资讯)– Novotech（诺为泰）是一家专门与生物技术公司合作、加快各个阶段先进新型疗法的开发、可提供全方位服务的国际性临床合同研究组织 (CRO)。现在诺为泰发布了一份新的行业报告，题为《胰腺癌——全球临床试验概况 (2024)》。 本新闻稿包含多媒体。此处查看新闻稿全文：...
View ArticleClik here to view.
Amneal and Shilpa Announce U.S. FDA Approval of BORUZU™, the First...
BRIDGEWATER, N.J. Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) and Shilpa Medicare Limited (“Shilpa”) announced U.S. Food and Drug Administration (FDA) approval of...
View ArticleClik here to view.
Ifinatamab Deruxtecan Continues to Demonstrate Promising Objective Response...
BASKING RIDGE, N.J. & RAHWAY, N.J. Results from an interim analysis of the dose-optimization part of the ongoing IDeate-Lung01 phase 2 trial showed ifinatamab deruxtecan (I-DXd) continues to...
View ArticleClik here to view.
Ivonescimab Monotherapy Reduced the Risk of Disease Progression or Death by...
MIAMI Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced data from the primary analysis of the Phase III HARMONi-2 trial featuring the novel, potential...
View ArticleClik here to view.
Novel Computational Pathology-Based TROP2 Biomarker for Datopotamab...
TOKYO & BASKING RIDGE, N.J. Results from an exploratory analysis of the TROPION-Lung01 phase 3 trial showed TROP2 as measured by quantitative continuous scoring (QCS), AstraZeneca’s proprietary...
View Article